NCT07122076View on ClinicalTrials.gov

GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

August 22, 2025

Primary Completion Date

August 21, 2028

Study Completion Date

August 21, 2028

Conditions

Autoimmune Diseases

Interventions

BIOLOGICAL

GT719 Injection

GT719 Injection

Trial Locations (1)

Unknown

RECRUITING

Shanghai Changzheng Hospital, Shanghai

Sponsors

Lead Sponsor

Grit Biotechnology

All Listed Sponsors

lead

Grit Biotechnology

INDUSTRY

NCT07122076 - GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases | Biotech Hunter | Biotech Hunter